Evaxion and expres²ion initiate research collaboration on a novel cytomegalovirus (cmv) vaccine candidate

HØrsholm, denmark, dec. 06, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, today announces that the company has signed a vaccine discovery collaboration agreement with expres2ion biotech holding ab's affiliate expres2ion biotechnologies aps (“expres2ion”) for the joint development of a novel cytomegalovirus (cmv) vaccine candidate.
EVAX Ratings Summary
EVAX Quant Ranking